2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1338 Association between GLP-1 receptor agonist initiation and warfarin time in therapeutic range: A retrospective paired cohort analysis

Matthew L Repp, MD, Gina Woodhouse, PharmD2, Lisa Pei Chu, MD3, Rebecca Swayngim, PharmD4, Elizabeth Le, PharmD5, Robert L Page, PharmD, MSPH6
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity. Although no established pharmacokinetic or pharmacodynamic interaction exists between GLP-1 RAs and warfarin, delayed gastric emptying, early satiety, and weight loss may alter dietary vitamin K intake, which may influence INR stability. However, the impact of GLP-1 RA initiation on warfarin anticoagulation stability has not been well characterized.

Objectives

To evaluate changes in warfarin anticoagulation control, specifically time in therapeutic range (TTR), in the 180 days following GLP-1 RA initiation compared with the 180 days prior.

Methods

This single-center retrospective cohort study identified 127 adult patients on chronic warfarin therapy who initiated a GLP-1 RA between January 2021 and December 2025. Eighty-nine patients (70%) were excluded. Of the excluded patients: 32 (36%) lacked adequate INR follow-up, defined as fewer than four INR checks in the 180 days before or after GLP-1 RA initiation, 9 (10%) had therapy interruption or confounding events, and 48 (54%) were excluded for other reasons including inability to confirm GLP-1 RA start date or consistent use, intolerance or cost-related discontinuation, or medication switches between GLP-1 agents. The remaining 38 patients met all inclusion criteria and comprised the final analytic cohort. INR outcomes were compared across matched 180-day windows before and after GLP-1 RA initiation. The primary outcome was change in TTR. Wilcoxon signed-rank tests were used as the primary statistical approach. Prespecified subgroup analyses were conducted by baseline INR stability, GLP-1 agent, GLP-1 indication, and warfarin indication.

Results

Thirty-eight patients were included (mean age 56.4 ± 15.2 years; 55.3% male). Twenty-two patients (57.9%) had multiple warfarin indications. The most common indications were DVT (39.5%), atrial fibrillation/flutter (36.8%), PE (36.8%), and CVA/TIA (28.9%). GLP-1 agents included subcutaneous semaglutide (60.5%) and tirzepatide (39.5%); indications for GLP-1 RA therapy were obesity alone (47.4%), combined obesity and T2DM (47.4%), and T2DM alone (5.3%). Baseline INR stability, defined as ≥70% TTR in the 180 days before GLP-1 RA initiation, was present in 31.6% (n = 12) of patients. Patient-specific INR goals were 2–3 in 76.3% (n = 29), 2.5–3.5 in 18.4% (n = 7), and non-standard ranges (2–2.5 or 3–4) in the remaining 5.3% (n = 2).

TTR declined significantly following GLP-1 RA initiation (median 57.1% pre vs. 50.0% post; median change −13.7%; Wilcoxon p = 0.0083). Mean INR did not change significantly (median change +0.01; p = 0.82). INR variability (SD) and supratherapeutic INR burden showed directional increases that did not reach statistical significance (p = 0.077 and p = 0.094, respectively).

The TTR decline was driven entirely by patients with stable baseline anticoagulation (median change −36.1%, p = 0.0005; n = 12), while those with unstable baseline INR showed no significant change (median change +0.9%, p = 0.86; n = 26; between-group p < 0.0001). Semaglutide was associated with a significant TTR decline (median change −10.0%, p = 0.017; n = 23). Tirzepatide showed a larger effect size (median change −15.8%) that did not reach significance (p = 0.17; n = 15); the subgroup was likely underpowered to detect an effect of this magnitude. Patients prescribed GLP-1 RAs for obesity alone had the largest significant TTR reduction (median change −19.3%, p = 0.009; n = 18). Among warfarin indication subgroups, patients anticoagulated for CVA/TIA demonstrated a significant TTR decline (median change −19.4%, p = 0.014; n = 11), as did those with atrial fibrillation/flutter (median change −10.9%, p = 0.049; n = 14).

Conclusions

GLP-1 RA initiation was associated with a significant decline in TTR in patients on chronic warfarin therapy, particularly those with previously stable anticoagulation. Similar directional effects were observed with both agents, although statistical significance was reached only for semaglutide, likely reflecting tirzepatide's smaller subgroup (n = 15 vs. n = 23) rather than a true difference in drug effect. The effect appears consistent across agents and is most pronounced in patients prescribed GLP-1 RAs for obesity. Enhanced INR monitoring is warranted following GLP-1 RA initiation, especially in well-controlled patients and those at elevated thromboembolic risk.

Matthew L Repp, MD: No relevant conflicts of interest to declare.